



MICHAEL L. PARSON, GOVERNOR • ROBERT J. KNODELL, ACTING DIRECTOR

TODD RICHARDSON, DIRECTOR

MO HEALTHNET DIVISION

P.O. BOX 6500 • JEFFERSON CITY, MO 65102-6500

WWW.DSS.MO.GOV • 573-751-3425

May 31st, 2022

Dear Pharmaceutical Manufacturer:

The MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) annual evaluation process. The Division is reviewing specific therapeutic classes, seeking supplemental rebate offers for maximum cost effectiveness for the MO HealthNet pharmacy program. Preferred drugs will be selected in each therapeutic class based on clinical effectiveness and the drugs' relative values within the therapeutic class net of supplemental rebates. These decisions will be made by MHD upon consideration of the recommendations made by the State of Missouri, MO HealthNet Drug Prior Authorization Committee (DPAC) and Drug Utilization Review Board (DURB).

At this time, supplemental rebate offers are requested for the following therapeutic categories; please note that the drug classes are divided into two groups with two different contract periods. Additionally, the class formerly known as the Respiratory Monoclonal Antibodies is now named the Targeted Immune Modulators, Miscellaneous Allergy and Asthma Related Monoclonal Antibodies and its annual review has been changed from March to June. Please note that all bids for all classes are due on **Friday, July 1st, 2022** by 5:00 pm Eastern.

Interpretive services are available by calling the Participant Services Unit at 1-800-392-2161.
Prevodilačke usluge su dostupne pozivom odjela koji učestvuje u ovom servisu na broj 1-800-392-2161.
Servicios Interpretativos están disponibles llamando a la unidad de servicios de los participantes al 1-800-392-2161.

AUXILIARY AIDS AND SERVICES ARE AVAILABLE UPON REQUEST TO INDIVIDUALS WITH DISABILITIES

TDD / TTY: 800-735-2966

RELAY MISSOURI: 711

Missouri Department of Social Services is an Equal Opportunity Employer/Program.

I. Group A – PDL Drug Classes traditionally reviewed at the September DPAC meeting of every year

Supplemental rebates will begin to accrue on **January 1st, 2023** and end **December 31st, 2023 (12 month contract)** for those drugs selected as preferred in the classes below, unless otherwise noted.

CARDIOVASCULAR

- Angiotensin Converting Enzyme (ACE) Inhibitors
- ACE Inhibitors/Calcium Channel Blocker Combination Agents
- ACE Inhibitors/Diuretic Combination Agents
- Angiotensin Receptor Blocker Agents (ARBs)
- Angiotensin Receptor Blocker/Diuretic Combination Agents
- Angiotensin Receptor Blocker/Beta Blocker Combination Agents
- Angiotensin Receptor Blocker/Calcium Channel Blocker Combination Agents
- Angiotensin Receptor Blocker/ -Nepriylsin Inhibitor Comb
- Anticoagulant Agents: Oral and Subcutaneous
- Antiplatelet Agents
- Beta Adrenergic Blockers and Diuretic Combination Agents
- Calcium Channel Blocker Agents (Dihydropyridines)
- Calcium Channel Blocker Agents (Non-Dihydropyridines)
- Direct Renin Inhibitors and Combination Agents
- Lipotropic Agents:
 - Homozygous Familial Hypercholesterolemia Products
 - Niacin and Combination Preparations
 - PCSK9 Inhibitors
 - Statins and Combination Products
 - Triglyceride Lowering Agents
- Sympatholytic Antihypertensive Agents

CENTRAL NERVOUS SYSTEM

- Anticonvulsants: Rescue Agents
- Attention Deficit Hyperactivity Disorder (ADHD) Agents
 - Long acting amphetamine agents
 - Short acting amphetamine agents
 - Long acting methylphenidate agents
 - Short acting methylphenidate agents
 - Non-stimulants
- Spinal Muscular Atrophy Agents

GASTROINTESTINAL

- Proton Pump Inhibitors

OPHTHALMOLOGY

- Agents for Dry eye

RESPIRATORY

- Pulmonary Hypertension Agents: Inhaled/Injectable
- Pulmonary Hypertension Agents: Oral
 - Endothelin Receptor Antagonists
 - Nitric Oxide Stimulators
 - Oral Prostacyclins
 - Inhaled Prostacyclins

Classes to be reviewed continue the next page

II. Group B – PDL Drug Classes traditionally reviewed at the June DPAC meeting of every year:

Supplemental rebates will begin to accrue on **January 1st, 2023** and end **September 30th, 2023 (nine month contract)** for those drugs selected as preferred in the classes below, unless otherwise noted.

ANTI-INFECTIVES

Cephalosporins - 1st Generation
Cephalosporins - 2nd Generation
Cephalosporins - 3rd Generation
Fluoroquinolones - Oral
GI Antibiotics
Macrolides
Penicillins
Tetracyclines
Vaginal Antibiotics

CENTRAL NERVOUS SYSTEM

Oral Multiple Sclerosis Agents
Self Injectable Multiple Sclerosis Agents
Injectable Physician Administered Multiple Sclerosis Agents

DERMATOLOGIC AGENTS:

Topical Antibiotics, Mupirocin

ENDOCRINE AND METABOLIC AGENTS

Agents for Bone Ossification
Bisphosphonates
Calcitonin Agents
Antihyperglycemic
Alpha Glucosidase Inhibitor
Amylin-Analogs
Biguanide
DPP-IV (Dipeptidyl Peptidase-4) Inhibitors & Combination Agents
GLP-1 Receptor Agonist and Related Agents

ENDOCRINE AND METABOLIC AGENTS (con't)

Insulin - Long Acting Analog & GLP-1 Agonist
Insulin - Long Acting Analogs
Insulin - Mixed
Insulin - Non-Analogs
Insulin - Rapid Acting
Meglitinide
Oral Sulfonylurea - (2nd Gen)
SGLT2-Inhibitors & Combination Agents
TZD & Combos
Antihyperuricemic Agents
LHRH, GHRH Antagonists, Oral
LHRH, GHRH Antagonists, Injectable
Pregnancy Maintaining Agent, Hormonal

GASTROINTESTINAL

Bile Salt Agents

HEMATOLOGICAL AGENTS

Agents for Thrombocytopenia
Colony Stimulating Agents (Leukocyte (WBC) Stimulants)
Erythropoiesis Stimulating Agents (ESAs)

Classes to be reviewed continue the next page



MICHAEL L. PARSON, GOVERNOR • ROBERT J. KNODELL, ACTING DIRECTOR

TODD RICHARDSON, DIRECTOR
MO HEALTHNET DIVISION
P.O. BOX 6500 • JEFFERSON CITY, MO 65102-6500
WWW.DSS.MO.GOV • 573-751-3425

IMMUNOLOGIC AGENTS

*Systemic Immunomodulators, Cryopyrin-Associated
Periodic Syndrome (CAPS) Agents*

*Targeted Immune Modulators ** see further
clarification and instructions in separate document***

IL-23 and/or IL-12 inhibitors

IL- 17A Antibody/IL-17 Receptor Antagonists

IL-6 Inhibitors

JAK Inhibitors for the indication of Atopic Dermatitis

*JAK Inhibitors for all indications excluding Atopic
Dermatitis*

Systemic Lupus Erythematosus (SLE)

TNF- Alpha Blockers and related products

Select Agents

*Miscellaneous Allergy and Asthma-Related Monoclonal Antibodies**

Miscellaneous Allergy and Asthma-Related Monoclonal Antibodies for the indications of Asthma

*Miscellaneous Allergy and Asthma-Related Monoclonal Antibodies for all indications excluding Atopic Dermatitis and
Asthma*

MISC

Methotrexate Products

RENAL and GENITOURINARY

Benign Prostatic Hyperplasia Agents

Electrolyte Depleters, Phosphate Lowering Agents

Electrolyte Depleters, Potassium Lowering Agents

Urinary Tract Antispasmodics

**please note that this PDL Class was formerly known as the Respiratory Monoclonal Antibodies and its annual review has
been moved from March to June)*

Please note the following deadlines:

Final supplemental rebate offers must be submitted to **Gainwell Technologies, LLC.** to Sandy Kapur at sandy.kapur@gainwelltechnologies.com via direct email by close of business on

5:00 p.m. Eastern on Friday, July 1st, 2022

We hope that you will take this opportunity to participate in a program that seeks to retain access to quality pharmaceuticals for Missouri's most vulnerable citizens.

Sincerely,

Josh Moore, PharmD
Director of Pharmacy
MO HealthNet Division

Interpretive services are available by calling the Participant Services Unit at 1-800-392-2161.
Prevodilačke usluge su dostupne pozivom odjela koji učestvuje u ovom servisu na broj 1-800-392-2161.
Servicios Interpretativos están disponibles llamando a la unidad de servicios de los participantes al 1-800-392-2161.

AUXILIARY AIDS AND SERVICES ARE AVAILABLE UPON REQUEST TO INDIVIDUALS WITH DISABILITIES

TDD / TTY: 800-735-2966

RELAY MISSOURI: 711

Missouri Department of Social Services is an Equal Opportunity Employer/Program.